Results 91 to 100 of about 5,710 (181)

Effekte von Evolocumab auf die vaskuläre Struktur und Funktion

Hintergrund und Ziele In der großangelegten Studie „Fourier Trial“ konnte ein positiver Effekt von Evolocumab auf die Reduktion des kardiovaskulären Risikos nachgewiesen werden.
Berner, Laura
core   +1 more source

Effects of residual inflammatory and cholesterol risks on cardiovascular events with evolocumab in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Lipids in Health and Disease
Background Evolocumab has shown significant reductions in low-density lipoprotein cholesterol (LDL-C) levels and incident cardiovascular events among acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Nonetheless,
Yahao Zhang, Kairu Li, Xiangwei Bo, Yanghui Zhang, Tingting Xiao, Huan Liu, Orion I. R. Chiara Villamil, Kui Chen, Jiandong Ding   +8 more
doaj   +1 more source

Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation After Myocardial Infarction

JACC: Basic to Translational Science
Summary: In a randomized trial with 55 participants from the EVACS (Evolocumab in Acute Coronary Syndrome) trials, patients with non–ST-segment elevation myocardial infarction (MI) or ST-segment elevation MI received a single dose of evolocumab or ...
Efthymios Ziogos, MD, Tarek Harb, MD, Ines Valenta, MD, Michael A. Vavuranakis, MD, PhD, Palmer L. Foran, BS, Marlene S. Williams, MD, Michael J. Blaha, MD, MPH, Allison G. Hays, MD, Steven R. Jones, MD, Thomas H. Schindler, MD, Steven P. Schulman, MD, Gary Gerstenblith, MD, Thorsten M. Leucker, MD, PhD   +12 more
doaj   +1 more source

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects

Clinical Pharmacology: Advances and Applications, 2019
Chao Liu,1 Hong Lu,2 Fei Yuan,1 Wei-Li Chen,1 Hong-Rong Xu,1 Hui Li,1 Cheng-Pang Hsu,3 Ogo Egbuna,3 Jihua Wu,2 Clapton Dias,3 Bassam Abosaleem,3 Jitesh Rana,3 Maria Laura Monsalvo,3 Xue-Ning Li,1 Zhigang Yu4 1Department of Clinical Pharmacology ...
Liu C, Lu H, Yuan F, Chen WL, Xu HR, Li H, Hsu CP, Egbuna O, Wu J, Dias C, Abosaleem B, Rana J, Monsalvo ML, Li XN, Yu Z   +14 more
doaj  

Sex differences in inflammatory biomarkers during long-term evolocumab therapy.

Background: Atherosclerotic cardiovascular disease remains a predominant cause of morbidity and mortality worldwide, driven by complex interactions between lipid metabolism and chronic inflammation.
Borghi C, Yerlitaş Taştan Sİ, Giovannini M, Zararsız G, Imbalzano E, Mitselman D, Fogacci F, Cicero AFG   +7 more
core   +1 more source

Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients

Background: Cardiac allograft vasculopathy is characterized by increased coronary intimal thickness and is a leading cause of death in heart transplant (HTx) recipients despite the routine use of statins.
Gjesdal, Grunde, Gude, Einar, Christiansen, Evald H., Eiskjaer, Hans, Karason, Kristjan, Fagerland, Morten W., Clemmensen, Tor S., Lommi, Jyri, Eiskjær, Hans, Gullestad, Lars, Arora, Satish, Lemström, Karl B., Pentikainen, Markku, Andreassen, Arne K., Broch, Kaspar, Bjørkelund, Elisabeth, Gustafsson, Finn, Berg, Erlend S., Bjorkelund, Elisabeth, Karason, Kristjan,   +19 more
core   +1 more source

Real-World Outcomes of Lipoprotein Apheresis in Homozygous Familial Hypercholesterolemia: A Single-Center Longitudinal Experience. [PDF]

J Clin Med
Mercan Sarıdaş F, Ersoy C, Özkalemkaş F, Hocaoğlu E, Yaşar M, Karatoprak K, Öz Gül Ö, Cander S, Ertürk E.   +8 more
europepmc   +1 more source

Early evolocumab improves lipid profile, inflammation and short-term outcomes in non-revascularized CHIP-NSTEACS patients: a retrospective cohort study. [PDF]

Front Cardiovasc Med
Jiang W, Liu M, Xiong X, Cheng J, Cheng F.   +4 more
europepmc   +1 more source

Comparing Systemic, Localized, and Focused Ultrasound-Mediated Delivery of Evolocumab (α-PCSK9) in a Murine Model of Glioblastoma 2303312

Introduction Key challenges in treating glioblastoma are the immunosuppressive tumor microenvironment and the blood-brain barrier (BBB).
Mustafa Khasraw, William McIntosh, Katayoun Ayasoufi, Wyatt Austin, Kathryn Blethen, Sarah Shapley, Angela Everhart, G Allan Johnson, Matthew Foster, Gerald Grant, Raymond Piatt   +10 more
core   +1 more source

Effect of Evolocumab on Grafts Post-Coronary Artery Bypass Surgery: Post-Hoc Analysis of Newton-CABG CardioLink-5. [PDF]

JACC Adv
Mancini GBJ, Kamimura C, Szarek M, Yeoh E, Ryomoto A, Teoh H, Quan A, Elituv R, Verma M, Misner E, Saha T, Yanagawa B, Jüni P, Koren MJ, Nicholls SJ, Bhatt DL, Leiter LA, Mazer CD, Verma S.   +18 more
europepmc   +1 more source